Previous close | 49.14 |
Open | 49.16 |
Bid | 49.07 x 900 |
Ask | 49.04 x 800 |
Day's range | 48.96 - 49.47 |
52-week range | 47.58 - 70.94 |
Volume | |
Avg. volume | 15,525,840 |
Market cap | 99.291B |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | 12.69 |
EPS (TTM) | 3.86 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 2.40 (4.88%) |
Ex-dividend date | 04 Apr 2024 |
1y target est | 52.41 |
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.
Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.